Corcept enrolls Corlux Phase III

CORT completed enrollment in the double-blind, placebo-controlled European Phase III Corcept 09 trial of Corlux mifepristone ( C-1073) to treat the psychotic features of psychotic major depression in 247 patients. The primary endpoint is proportion of patients with at least a 50% improvement in the brief psychiatric rating scale positive symptom subscale (BPRS PSS) at day seven and day 28. A secondary endpoint is the proportion of patients with at least a 50% improvement in the BPRS PSS at day seven and day 56. Data are expected in September. ...